

Form TO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
50634-BASerial No.  
10/646,493INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Eric Rose et al.Filing Date  
August 21, 2003

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JRL	US 5,839,443	Nov. 24, 1998	Eric Rose, et al.	128	898	
JRL	US 09/053,872		Eric Rose, et al.			April 1, 1998

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JRL	Bazan, J.F., "Big rigs in blood coagulation," <u>Nature</u> 380: 21-23, 03/1996
JRL	Benedict, C.R. et al., "Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model," <u>J. Clin. Invest.</u> , 88: 1760-1765, 1991.
JRL	Benedict, C.R. et al., "Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms," <u>Texas Heart Institute Journal</u> , 21: 86-90, 1994
JRL	Berntorp, E., "Biochemical and in vivo properties of high purity factor IX concentrates," <u>Thrombosis and Haemostasis</u> 70(5): 768-773, 11/1993
JRL	Freedman, S.J. et al., "Structure of the metal-free $\gamma$ -carboxyglutamate acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy," <u>J. Biol. Chem.</u> , 270(14): 7980-7987, 04/1995
JRL	Furie, B.C. and Furie, B., "Biosynthesis of factor IX: implications for gene therapy," <u>Thrombosis and Haemostasis</u> , 74(1): 274-277 (1995)
JRL	Iberti, T.J. et al., "Abnormal coagulation profile in brain tumor patients during surgery," <u>Neurosurgery</u> , 34(3): 389-395, 03/1994
JRL	Kirchhofer, et al., "Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model," <u>Arterioscler. Thromb. Vasc. Biol.</u> , 15: 1098-1106 (1995)


EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

December 16, 2004

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
50634-BASerial No.  
10/646,493INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Eric Rose et al.Filing Date  
August 21, 2003

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JR</i>	Kuwabara, K. et al., "Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries," <u>J. Biol. Chem.</u> , 270(14): 8179-8187, 04/1995
<i>JR</i>	Miyata, T. et al., "Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling," <u>Brit. J. Of Haematol.</u> , 88(1): 156-165, 09/1994
<i>JR</i>	Santagostino, E. et al., "Markers of hyper coagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery," <u>Thrombosis and Haemostasis</u> , 71(6): 737-40, 06/1994
<i>JR</i>	Wacey, A.I. et al., "Determinants of the factor IX mutational spectrum in hemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein," <u>Hum. Genet.</u> , 94(6): 594-609, 12/1994
<i>JR</i>	Warrier, I. et al., "Safety of high doses of a monoclonal antibody-purified factor IX concentrate," <u>Am. J. Of Hematol.</u> , 49(1): 92-94, 05/1995
<i>JR</i>	Wong, A.G. et al., "Relative efficacy of active site-blocked factors IXa Xa in a model of venous thrombosis," <u>Supplement I Circulation</u> , Abstract # 3293 p. I-686, Vol. 92, No. 8. 10/1995

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

December 16, 2004

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.